Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Sierra Natl BK Tehachapi Calif (MM) Charts. Click Here for more Sierra Natl BK Tehachapi Calif (MM) Charts.](/p.php?pid=staticchart&s=N%5ESIRT&p=8&t=15)
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs to
treat diseases of aging, announced today that it will be presenting at
the 6th Annual Metabolic Diseases Drug Discovery and Development World
Summit in San Diego, California. Jill Milne, Ph.D., Senior Director of
Biology at Sirtris, will deliver a keynote address “SIRT1
Activation: A Novel Mechanism for Treating Type 2 Diabetes.”
Her presentation is scheduled to be delivered at 8:45 am PST on Tuesday,
July 17, 2007.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small molecule
drugs with the potential to treat diseases associated with aging,
including metabolic diseases such as Type 2 Diabetes. Our drug
candidates are designed to mimic certain beneficial health effects of
calorie restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that
control the aging process. The company's headquarters are in Cambridge,
Massachusetts.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
concerning Sirtris Pharmaceuticals, its product candidates, and those
candidates' clinical potential. These forward-looking statements about
future expectations, plans and prospects of Sirtris Pharmaceuticals
involve significant risks, uncertainties and assumptions, including
risks related to the lack of results that would provide a basis for
predicting whether any of the Company’s
product candidates will be safe or effective, or receive regulatory
approval, the Company's potential inability to initiate and complete
preclinical studies and clinical trials for its product candidates, the
fact that none of the Company's product candidates has received
regulatory approvals, the potential inability of the Company to gain
market acceptance of the Company's product candidates, and those other
risks factors that can be found in the Company's filings with the
Securities and Exchange Commission. Actual results may differ materially
from those Sirtris Pharmaceuticals contemplated by these forward-looking
statements. Sirtris Pharmaceuticals does not undertake to update any of
these forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.